The up-regulation of PD-L1 is an adaptive mechanism mediating the resistance to anti-PD-1 immunotherapy.50 Since the knockdown of SIRT7 can lead to more CD8+T cells infiltration in TME and induce prominent down-regulation of PD-L1, we proposed that SIRT7 deficiency could synergize with anti-PD-1 immunotherapy in melanoma. The gene discussed is CD8A; the disease is melanoma.